FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1025 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows September 12, 2018 After Being Told a Lump Was Benign, Teenager Learns She Has... August 14, 2021 Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not... April 8, 2025 Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed... January 13, 2025 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan When You Have to Make Decisions for a Loved One With... COVID-19 Takes the Life of a Widowed Mother of 6 Who... EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary...
